Cost Evaluation Analysis of Genetic Testing and Tailored Adjuvant Imatinib in Patients With Resected High-Risk GI Stromal Tumors: The Brazilian Perspective
PURPOSEMutations of the KIT gene are the molecular hallmark of most GI stromal tumors (GISTs). Imatinib has revolutionized GIST treatment. Adjuvant imatinib for 3 years is the standard of care for high-risk resected GIST. However, the GIST molecular biologic profile has found different responses to...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Clinical Oncology
2023-09-01
|
| Col·lecció: | JCO Global Oncology |
| Accés en línia: | https://ascopubs.org/doi/10.1200/GO.23.00070 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|